SARS Capital Revenue and Competitors
Estimated Revenue & Valuation
- SARS Capital's estimated annual revenue is currently $14.6M per year.
- SARS Capital's estimated revenue per employee is $140,000
Employee Data
- SARS Capital has 104 Employees.
- SARS Capital grew their employee count by -3% last year.
SARS Capital's People
| Name | Title | Email/Phone |
|---|
SARS Capital Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.7M | 5 | 25% | N/A | N/A |
#2 | $22.7M | 162 | 32% | N/A | N/A |
#3 | $75M | 294 | 7% | N/A | N/A |
#4 | $15M | 57 | 6% | N/A | N/A |
#5 | $1.7M | 6 | 0% | N/A | N/A |
#6 | $3.5M | 14 | -12% | N/A | N/A |
#7 | $7.5M | 84 | 18% | N/A | N/A |
#8 | $7.7M | 55 | 10% | N/A | N/A |
#9 | $0.4M | 3 | 0% | N/A | N/A |
#10 | $281.1M | 2008 | 1% | N/A | N/A |
What Is SARS Capital?
N/A
Total Funding
104
Number of Employees
$14.6M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
SARS Capital News
2022-04-20 - Low Vaccination Rates in Children, Non-Adherence to COVID ...
Nearly 100 school children in the NCR region of the capital have been infected with SARS-CoV-2 the virus causing the COVID-19 disease in...
2022-04-17 - SpikImm, a Biotech Company Founded by Truffle Capital and ...
SpikImm, a Biotech Company Founded by Truffle Capital and Institut Pasteur, Announces That Its Monoclonal Antibody Neutralises All SARS-COV-2...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $28.1M | 104 | 0% | N/A |
#2 | $17.2M | 104 | -25% | N/A |
#3 | $18.7M | 104 | 4% | N/A |
#4 | $28.1M | 104 | -3% | N/A |
#5 | $21.8M | 104 | 20% | N/A |